US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

Cystic renal cell carcinoma is a predominantly cystic lesion with a small solid component (25% or less). Renal cell carcinoma usually presents as a solid mass; however, in 10–22% of cases ...

Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

Brandy Verdin, 49, lives with her husband in Gray, Louisiana. She was diagnosed with Stage IV renal cell carcinoma in May 2023.

Figure 1: Characterization of the hybrid cell vaccine. The hybrid cell vaccination was well tolerated by all patients. There were no serious adverse effects or any clinical signs of autoimmune ...